2 2 2000 DEC 2 3 2000		Approved for use through 07/31/2006. OMB 0651-0031 at and Trademark Office; U.S. DEPARTMENT OF COMMERCE
		on of information unless it displays a valid OMB control number.  09/990,522
TRANSMITTALBADEME FORM	Filing Date First Named Inventor	November 21, 2001
	Art Unit	Choy-Pik Chiu, et al.
(to be used for all correspondence after initial filin	Examiner Name	1636 Quang Nguyen
Total Number of Pages in This Submission	6 Attorney Docket Number	097/002
	ENCLOSURES (Check all that	(apply)
Certified Copy of Priority	Drawing(s)  Licensing-related Papers  Petition  Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Address  Terminal Disclaimer  Request for Refund  CD, Number of CD(s)  Remarks  1. PTO Form 1449 (1 page) + co	Other Enclosure(s) (please Identify below):
SIGNATU	IRE OF APPLICANT, ATTORNI	EY, OR AGENT
or Individual name Signature	J. Michael Schiff, Registra	tion No. 40,253
Date	Docember 19,200	3
CER CER	TIFICATE OF TRANSMISSION	/MAILING
I hereby certify that this correspondence is bein sufficient postage as first class mail in an envelopment date shown below.	g facs mile transmitted to the USPTO or ope addressed to: Commissioner for Pat	deposited with the United States Postal Service with ents, P.O. Box 1450, Alexandria, VA 22313-1450 on
Typed or printed name	/ KARTX MAKAUSA	y
Signature	makausky	Date December 19, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

DEC 2.2 2013  Lunder Ste Paperwork Restliction Act of 1995 the persons are required.	PTO/SB/17 (10-03 Approved for use through 07/31/2006. OMB 0651-003 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE uired to respond to a collection of information unless it displays a valid OMB control number
FEETRANSMITTA	Application Number 09/990,522
for FY 2004	Filing Date November 21, 2001
Effective 10/01/2003. Patent fees are subject to annual revision.	First Named Inventor Choy-Pik Chiu, et al.
	Examiner Name Quang Nguyen
Applicant claims small entity status. See 37 CFR 1.27	Art Unit 1636
TOTAL AMOUNT OF PAYMENT (\$) 180	Attorney Docket No. 097/002
METHOD OF PAYMENT (check all that apply)	FEE CALCULATION (continued)
Check	Large Entity   Small Entity
Total Claims	1503 640 2503 320 Plant issue fee 1460 130 1460 130 Petitions to the Commissioner 1807 50 1807 50 Processing fee under 37 CFR 1.17(q)
Large Entity   Small Entity Fee Fee Fee Fee <u>Fee Description</u>	1806 180 1806 180 Submission of Information Disclosure Stmt
Code (\$)   Code (\$)   1202 18   2202 9 Claims in excess of 20	8021 40 8021 40 Recording each patent assignment per property (times number of properties)
1201 86 2201 43 Independent claims in excess of 3	1809 770 2809 385 Filing a submission after final rejection (37 CFR 1.129(a))
1203 290 2203 145 Multiple dependent claim, if not paid	1810 770 2810 385 For each additional invention to be
1204 86 2204 43 ** Reissue independent claims over original patent	examined (37 CFR 1.129(b))  1801 770 2801 385 Request for Continued Examination (RCE)
1205 18 2205 9 ** Reissue claims in excess of 20 and over original patent	1802 900 1802 900 Request for expedited examination of a design application
	Other fee (specify)
SUBTOTAL (2) (\$) U  **or number previously paid, if greater; For Reissues, see above	*Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 180

SUBMITTED BY

Name (Print/Type)

J. Michael Schiff
Registration No. (Attornev/Agent)

All Date


(Complete (if applicable))

Telephone (650) 473-7715

Date

WARNING: Information on this form may become public. Credit card information should not be included on this form. Plovide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors: Choy-Pik Chiu & Robert Kay

Filing Date: November 21, 2001

Serial No: 09/990,522

Docket: 097/002

Title: TOLERIZING ALLOGRAFTS OF

PLURIPOTENT STEM CELLS

Art Unit: 1636

Examiner: Quang Nguyen, Ph.D.

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR § 1.97(c)(2)

Commissioner for Patents & Trademarks Washington, D.C. 20231

Dear Sir:

The information listed in the accompanying form PTO-1449 and provided herewith may be material to examination of this application and is submitted in compliance with the duty of disclosure under 37 CFR § 1.56. The Examiner is requested to make this information of record in the application.

This Information Disclosure Statement is not to be construed as a representation that a full search for relevant information has been made, that all relevant information has been found, or that the information provided with this Statement is considered to be material to patentability of the claimed invention as defined under 37 CFR § 1.56(b).

12/31/2003 BSAYASI1 00000014 071139 09990522

This Information Disclosure Statement is being filed after the first Office Action on the merits, pursuant to 37 CFR § 1.197(c)(2). Authorization to charge Deposit Account 07/1139 with the fee therefor under 37 CFR § 1.117(p) is provided in the accompanying fee calculation sheet.

Should any other fees be required for further consideration of the application, the Commissioner is hereby authorized to charge such fees (or credit any overpayment) to the Deposit Account.

Respectfully submitted,

J. Michael Schiff

Registration No. 40,253

GERON CORPORATION 230 Constitution Drive Menlo Park, CA 94025 Telephone: (650) 473-7715

Fax: (650) 473-8654

December 18, 2003

(modified) DEC 23 2003 Inf rmati n Disposur Statement By Applicant

ocket: 097/002

U.S.S.N. 09/990,522

Stitle: Tolerizing Allografts of Pluripotent Stem Cells inventors: Choy-Pik Chiu, Robert M. Kay

RADEMARK Filing Date: November 21, 2001

Examiner: Q. Nguyen Group: 1636

U.S. Patent D cuments

Examiner Initial	Ref.	Patent No.	Filing Date	Issue Date	Class/ Subclass	Inventors:	Title:
	FA	6,368,636	Oct 26/99	Apr. 9/02	424/577	McIntosh et al.	Mesenchymal stem cells for prevention and treatment of immune responses in transplantation

## Foreign Patent or Published Foreign Patent Application

	Examiner	Ref.	Document	Publ.	Juris-	Title:	Translation	
L	Initial	1101.	No.	Date	diction	1106.	Yes	No
(NONE)								

## **Other Documents**

Examiner Initial	Ref.	Author, Title, Date, Source
	FB	Barber et al. Long-term reults of a controlled prospective stuty with transfucion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation 51:70, 1991. (abstract)
	FC	Fontes et al. Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancras islet transplantation. Lancet 344(8916):151, 1994. (abstract)
	FD	Kuhr et al. Tolerance to vascularized kidney grafts in canine mixed hematopoietic chimeras. Transplantation 73:1487, 2002.
	FE	Menaché et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J. Am. Coll. Cardiol. 41:1078, 2003.
	FF	Rifle & Mousson. DOnor-derived hematopoietic cells in organ transplantation: A major step toward allograft tolerance? Transplantation 75 Suppl: 3S, 2003.
	FG	Seung et al. Hematopoietic chimerism and central tolerance created by peripheral-tolerance induction without myeloablative conditioning. J. Clin. Invest. 112:795, 2003.
	FH	Wekerle et al. Mechanisms of tolerance induction through the treansplantation of donor hematopoietic stem cells: Central versus peripheral tolerance. Transplantation 75 suppl:21S, 2003.
	FI	Xu et al. Characterization and enrichment of cardiomyocytes derived form human embryonic stem cells. Circ. Res. 91:501, 2002.
	FJ	Yao et al. Long-term outcome of fetal cell transplantation on postinfarctoin ventricular remodeling and function. J. Molec. Cell. Cardiol. 35:661, 2003.

Examiner	Date Considered